CD161
CD161 is a potent, selective and orally bioavailable bromodomain and extra-terminal (BET) bromodomain inhibitor with an IC50s of 28.2 nM and 7.2 nM for BRD4 BD1 and BRD4 BD2, respectively. CD161 has good anticancer activity[1].
Product Specifications
CAS Number
1627716-22-6
UNSPSC
12352005
Target
Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cd161.html
Solubility
10 mM in DMSO
Smiles
CC1=NC(C2=CC=NC3=CC=CC=C23)=C4C(NC5=C4C=C(OC)C(C6=C(C)ON=C6C)=C5)=N1
Molecular Formula
C26H21N5O2
Molecular Weight
435.48
References & Citations
[1]Zhao Y, et al. Structure-Based Discovery of 4- (6-Methoxy-2-methyl-4- (quinolin-4-yl) -9H-pyrimido[4,5-b]indol-7-yl) -3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor. J Med Chem. 2017 May 11;60 (9) :3887-3901.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
PB9250-APC 100 µg/Vial
Anti-CD63 Antibody Picoband® (APC Conjugate)
Sign In for Pricing
View Details 
orb1661843 96 Tests
Rat Adam17/Disintegrin and metalloproteinase domain-containing protein 17 ELISA Kit
Sign In for Pricing
View Details 